ライフサイエンスコーパス: xerostomia

1 (keratoconjunctivitis sicca) and dry mouth (xerostomia).

2 seases and that result in hyposalivation and xerostomia.

3 Amifostine reduced acute and chronic xerostomia.

4 recently in the scintigraphic evaluation of xerostomia.

5 lly, CD patients were more likely to develop xerostomia.

6 All patients showed grade 1 xerostomia.

7 an seven cycles of (225)Ac-PSMA RLT reported xerostomia.

8 minary evidence of genetic susceptibility to xerostomia.

9 y retention and xeropthalmia, and 6 of 8 had xerostomia.

10 mentary option for the management of primary xerostomia.

11 mon adverse events were anemia, fatigue, and xerostomia.

12 ndividual classifiers in prediction of early xerostomia.

13 the risk of salivary gland hypofunction and xerostomia.

14 cidate the role of genetic susceptibility to xerostomia.

15 of OPC survivors reported moderate to severe xerostomia.

16 ed bilateral radiotherapy with no history of xerostomia.

17 cal trial in patients with radiation-induced xerostomia.

18 herapy can develop chronic radiation-induced xerostomia.

19 f acupuncture for treating radiation-induced xerostomia.

20 ative for the treatment of radiation-induced xerostomia.

21 ase minor side effects like pharyngalgia and xerostomia.

22 e was also used to determine the severity of xerostomia.

23 outcomes included efficacy, pain scores, and xerostomia.

24 rapy of head and neck cancer (HNC) including xerostomia.

25 que biomarkers for prediction of early-onset xerostomia.

26 development of hyposalivation in DM-induced xerostomia.

27 options for the patient with DM experiencing xerostomia.

28 benefit for management of radiation-induced xerostomia.

29 y presents as keratoconjunctivitis sicca and xerostomia.

30 y glands cause reduced salivation leading to xerostomia.

31 s also experienced subjective improvement in xerostomia.

32 sparing IMRT reduces the incidence of severe xerostomia.

33 dissection pain and dysfunction, as well as xerostomia.

34 of grade 3 xerostomia, and none had grade 4 xerostomia.

35 weight loss, disfigurement, depression, and xerostomia.

36 maging saliva production and contributing to xerostomia.

37 ective in treating chronic radiation-induced xerostomia 1 or more years after the end of radiotherapy

38 nts reporting grade 2 or 3 radiation-induced xerostomia 12 months or more postradiotherapy for head a

39 esophagus, 4.7%; mucous membranes, 3.1%; and xerostomia, 3.1%.

40 89% vs 76%), as were dysphagia (49% vs 31%), xerostomia (45% vs 33%), and gastrostomy tube dependence

41 Toxicities were mild, with rash (90%) and xerostomia (54%) being most frequent.

42 mplications from cancer treatment, including xerostomia (66 of 73 [90%]), caries (35 of 73 [48%]), an

43 n AEs: 9 (100%) reported dysgeusia; 7 (78%), xerostomia; 7 (78%), mucositis or oral pain; 8 (89%), dy

44 of 88; 83.0%), arthritis (22 of 45; 48.9%), xerostomia (9 of 17; 52.9%), neurotoxicities (11 of 15;

45 Genetic susceptibility for xerostomia, a common sequela of radiotherapy and chemora

46 Xerostomia, a secondary end point, was assessed using th

47 ure produced greater improvement in reported xerostomia (adjusted difference in Xerostomia Inventory

48 Eight patients with preexisting xerostomia after (177)Lu-PSMA showed no worsening after

49 Newly diagnosed grade 1 or 2 xerostomia after TAT was observed in 5 patients.

50 , and 236 (68%) of the 347 patients reported xerostomia after the first cycle of (225)Ac-PSMA RLT.

51 clinical side effects (2 cases of transient xerostomia and 1 of nausea, all grade 1 or 2), as well a

52 ar posttreatment, 61% of patients had severe xerostomia and 47% had compromised swallowing.

53 ead and neck cancer causes acute and chronic xerostomia and acute mucositis.

54 documented adverse effects, most common are xerostomia and cheilitis.

55 Xerostomia and chronic kidney disease became more common

56 Late complications of treatment included xerostomia and hoarseness.

57 the physiological mechanisms associated with xerostomia and hyposalivation.

58 IMRT significantly reduces the incidence of xerostomia and leads to recovery of saliva secretion and

59 ent salivary gland hypofunction which causes xerostomia and oral infections.

60 Xerostomia and reduced mouth opening are negatively asso

61 s may have xerostomia; the mechanisms of the xerostomia and salivary gland (SG) hypofunction remain c

62 The prevalence of xerostomia and salivary gland hypofunction appears to be

63 ell counts are significantly associated with xerostomia and salivary gland hypofunction in a populati

64 The association of xerostomia and salivary gland hypofunction with HIV infe

65 r =3 acute mucositis, and grade > or =2 late xerostomia and were based on the worst toxicity reported

66 Complaints of a dry mouth (xerostomia) and sialoadenitis are frequent side effects

67 ], (2) salivary dysfunction (saliva flow and xerostomia), and (3) maximum mouth-opening measurement.

68 Only two patients complained of grade 3 xerostomia, and none had grade 4 xerostomia.

69 Swallowing abnormalities, xerostomia, and poor dentition may result in dietary ada

70 [eNOS]) are altered in the onset of diabetic xerostomia; and 2) to determine whether the changes in n

71 However, side effects such as xerostomia are severe and irreversible.

72 Xerostomia as a result of salivary gland damage is a per

73 ef Pain Inventory-Short Form (BPI-SF), and a xerostomia assessment, all completed at each treatment c

74 jectives of this project are to establish if xerostomia associates with SG and HCV infection and to c

75 The rate of grade 2 xerostomia at 1 year from start of IMRT was 13.5%.

76 in 73 of 82 alive patients; grade 2 or worse xerostomia at 12 months was significantly lower in the I

77 proportion of patients with grade 2 or worse xerostomia at 12 months, as assessed by the Late Effects

78 nt factors and the incidence of pharyngalgia/xerostomia at 30 min post-procedure were assessed.

79 One patient reported no xerostomia at all.

80 In clinical application, severe xerostomia became the dose-limiting toxicity if treatmen

81 d to mild transient bone marrow toxicity and xerostomia because of uptake of the small-molecule agent

82 common toxicity 6 months after treatment was xerostomia, but this occurred in 3% or less of patients

83 saliva suggest that HCV infection can cause xerostomia by mechanisms distinct from SS.

84 Xerostomia can be caused by medications, chronic disease

85 Xerostomia can eventually lead to difficulty in swallowi

86 ng was used to ensure that the proportion of xerostomia cases was consistent across both subsets.

87 to reduce the salivary symptoms of pain and xerostomia caused by 131I therapy for papillary and foll

88 and composition alterations, development of xerostomia, characteristics of patients at risk for sali

89 t demonstrate a benefit of ART in decreasing xerostomia compared with standard IMRT.

90 Any candidates with subjective xerostomia, conditions or medications associated with dr

91 filtration of exocrine tissues, resulting in xerostomia (dry mouth) and keratoconjunctivitis sicca (d

92 the salivary and lacrimal glands leading to xerostomia (dry mouth) and xerophthalmia (dry eyes).

93 Current treatments for xerostomia/dry mouth are palliative and largely ineffect

94 patients that suffer from chronic dry mouth (xerostomia) due to salivary gland injury from radiation

95 appeared to reduce mucositis, dysphagia, and xerostomia during hyperfractionated radiotherapy (n = 40

96 -item AE-focused measure of pain, dysphagia, xerostomia, dysgeusia, voice changes, dermatitis, fatigu

97 for the millions of patients who suffer from xerostomia each year.

98 requent clinical side effects were grade 1-2 xerostomia, fatigue, and inappetence.

99 Amifostine reduced grade > or =2 acute xerostomia from 78% to 51% (P<.0001) and chronic xerosto

100 stomia from 78% to 51% (P<.0001) and chronic xerostomia grade > or = 2 from 57% to 34% (P=.002).

101 hortened (5 v 26 days), and the incidence of xerostomia grade >/= 2 was lower (67% v 80%), favoring p

102 ncluded the incidence of grade > or =2 acute xerostomia, grade > or =3 acute mucositis, and grade > o

103 vary glands and resulting hyposalivation and xerostomia have a substantial impact on patient health,

104 hypofunction with decreased salivary output, xerostomia, impaired ability to chew and swallow, increa

105 Except for mild reversible xerostomia in 2 patients, no long-term side effects were

106 The most prevailing cause of xerostomia in elderly persons is the use of anticholiner

107 ention of salivary gland hypofunction and/or xerostomia in patients with head and neck cancer, there

108 le classifiers for prediction of early-onset xerostomia in radiotherapy of HNC.

109 iated with higher risk of moderate to severe xerostomia in six genomic regions (2p13.3, rs6546481, Mi

110 We discuss approaches to quantify xerostomia in the clinic, including the advantages and l

111 lved acute inflammation and SMG dysfunction (xerostomia) in response to LPS that is similar to human

112 Procedure duration and recent pharyngalgia/xerostomia increased risk of pharyngalgia/xerostomia wit

113 This suggests that different threshold for xerostomia injury and recovery.

114 gement of salivary gland hypofunction and/or xerostomia, intermediate-quality evidence supports the u

115 o develop salivary gland hypofunction and/or xerostomia, interventions include topical mucosal lubric

116 reported xerostomia (adjusted difference in Xerostomia Inventory = -5.8; 95% CI, -0.9 to -10.7; P =

117 The Xerostomia Inventory questionnaire was also used to dete

118 ions in salivary flow rate, composition, and xerostomia inventory score were analyzed.

119 urthermore, patients completed the validated xerostomia inventory.

120 secondary end point, was assessed using the Xerostomia Inventory.

121 Xerostomia is a common consequence of radiotherapy in he

122 Xerostomia is a common side effect of radiation therapy

123 Xerostomia is a common side effect of RLT because of the

124 Xerostomia is a common side-effect.

125 Xerostomia is a major toxic effect associated with inten

126 Xerostomia is defined as dry mouth resulting from a chan

127 Studies have shown that xerostomia is more common in females at the onset of DM.

128 Because xerostomia is one of the most important clinical feature

129 Xerostomia is the most common late side-effect of radiot

130 s were seen between randomised groups in non-xerostomia late toxicities, locoregional control, or ove

131 , dysphagia, coated tongue, nocturnal cough, xerostomia, lump in the throat, asthma-like symptoms, re

132 saliva, a reduction in salivary flow (as in xerostomia) may diminish the oral self-defense mechanism

133 The primary end point was the frequency of xerostomia, measured by stimulating salivary flow with p

134 ute adverse effects were associated with RT (xerostomia, mucositis, and local skin toxicity).

135 (n = 10), advanced age (n = 7), concern for xerostomia (n = 4), or patient refusal (n = 2).

136 Xerostomia, nausea, and fatigue occurred sporadically (<

137 The commonest toxicity seen was grade I-II xerostomia, observed in 81% of patients.

138 Pharyngalgia/xerostomia occurred in 18.7% of patients at 30 min after

139 Xerostomia occurred in 8%.

140 (42 [72%] IMPT vs 217 [93%] IMRT; P < .001), xerostomia of grade 2 or greater (12 [21%] IMPT vs 68 [2

141 ere was a significant difference for chronic xerostomia of grade 2 or greater (6 IMPT [11%] vs 22 IMR

142 The crude rates of xerostomia of grade 3 or greater and feeding tube use we

143 ciated with lower risk of moderate to severe xerostomia, of which only one mapped to specific genomic

144 None of these individuals had subjective xerostomia or dry eyes.

145 In people with CD, xerostomia or dry mouth is a common complication.

146 f primary, idiopathic mucosal mouth dryness (xerostomia or dry mouth) in subjects without systemic di

147 association with postoperative pharyngalgia/xerostomia (OR, 8.09 [95% CI, 4.197-6.312]).

148 uality of life measures, perceived thirst or xerostomia, or dietary sodium intake.

149 Xerostomia, or dry mouth, is a common side effect of hea

150 the prevalence of sialadenitis, stomatitis, xerostomia, or dysgeusia over the next 6 mo (P > 0.05).

151 induced toxic effects, such as mucositis and xerostomia, over conventional photon radiation therapy,

152 us elders (N = 133) and a clinical sample of xerostomia patients (N = 85).

153 Consistent with the low saliva flow and xerostomia, patients showed changes in several markers o

154 sea, hot flashes, fatigue, radiation-induced xerostomia, prolonged postoperative ileus, anxiety/mood

155 submandibular/sublingual saliva samples and xerostomia questionnaire responses were collected.

156 At week 4, Xerostomia Questionnaire scores revealed significant bet

157 ficant between-group differences, with lower Xerostomia Questionnaire scores with TA vs SOH (TA: 50.6

158 Patient-reported outcomes for xerostomia (Xerostomia Questionnaire, primary outcome) and quality o

159 the University of Michigan patient-reported xerostomia questionnaire.

160 ed less acute dysphagia grade >=3 and better xerostomia-related quality of life in the dose reduction

161 se, refers to keratoconjunctivitis sicca and xerostomia resulting from immune lymphocytes that infilt

162 e (SS) is characterized by xerophthalmia and xerostomia resulting from loss of secretory function due

163 racterized by keratoconjunctivitis sicca and xerostomia resulting from lymphocytic infiltrates of the

164 All subjects had normal oral exams, xerostomia scores and unstimulated whole-mouth salivary

165 were significantly associated with increased xerostomia severity (P = 0.002, P = 0.006, and P = 0.015

166 At 12 months xerostomia side-effects were reported in 73 of 82 alive

167 igraphy, patient-reported outcomes (Eisbruch xerostomia-specific questionnaire and the MD Anderson Sy

168 identify whether reduced saliva secretion or xerostomia symptoms are risk indicators for impaired tas

169 the present study evaluates the severity of xerostomia symptoms in people with CD.

170 s present better tolerability with regard to xerostomia than previous regimens of at least 100 kBq/kg

171 such an effect could underlie the dry mouth (xerostomia) that occurs as an unexplained side-effect of

172 Xerostomia, the subjective sensation of 'dry mouth' affe

173 Up to 55% of these patients may have xerostomia; the mechanisms of the xerostomia and salivar

174 Current xerostomia therapies only provide temporary symptom reli

175 Xerostomia was assessed based on "yes" responses to a dr

176 Patient-reported cancer treatment-related xerostomia was assessed using the MD Anderson Symptom In

177 nts, information regarding treatment-induced xerostomia was available, and 236 (68%) of the 347 patie

178 Confirmation of xerostomia was determined by increased water intake and

179 Transient xerostomia was observed in 23 (28%) patients.

180 Xerostomia was seen in 85% of patients but was not sever

181 At 24 months, grade 2 or worse xerostomia was significantly less common with IMRT than

182 Xerostomia was the only mentionable clinical side effect

183 variants associated with moderate to severe xerostomia, we conducted a GWAS of 359 long-term orophar

184 Minimal grade 3 and lack of grade 4 xerostomia were encouraging.

185 Eighteen HCV-infected patients with xerostomia were evaluated for SG dysfunction; 6 of these

186 Subjects with xerostomia were managed either with standard management

187 Only limited signs of xerostomia were observed after the treatment.

188 ificant reductions in pain, dysfunction, and xerostomia were observed in patients receiving acupunctu

189 prognoses results in more people living with xerostomia, which highlights the mounting need for resto

190 ient-reported sensation of dry mouth, termed xerostomia, which significantly reduces quality of life

191 reasonable), and to decrease acute and late xerostomia with fractionated radiation therapy alone for

192 ncer, which showed reduced acute and chronic xerostomia with preserved antitumour response, some inst

193 ia/xerostomia increased risk of pharyngalgia/xerostomia with SJOV during endoscopy.

194 ed to identify risk factors for pharyngalgia/xerostomia with SJOV during gastrointestinal endoscopy.

195 iness with TCAs, SNRIs, and anticonvulsants; xerostomia with TCAs; and peripheral edema and burning s

196 ed with lacrimal dysfunction (P = 0.010) and xerostomia with xerophthalmia (r = 0.32, P = 0.001); and

197 ths of radiotherapy and those recovered from xerostomia within 18 months post-radiotherapy.

198 showed that procedure time and pharyngalgia/xerostomia within 2 weeks were independent risk factors.

199 dose distribution in patients that developed xerostomia within 6 months of radiotherapy and those rec

200 Patient-reported outcomes for xerostomia (Xerostomia Questionnaire, primary outcome) a